Targeting RasGRP3 and Protein Kinase D to treat Uveal Melanoma
RasGRP3 and Protein Kinase D as therapeutic targets for Uveal Melanoma
This study is looking for new treatments for uveal melanoma, a serious eye cancer, by exploring how a protein called RasGRP3 affects the disease, with the hope of finding better options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11009582 on NIH RePORTER |
What this research studies
This research focuses on finding new therapies for uveal melanoma, a deadly form of eye cancer that often spreads to the liver. The team is investigating the role of RasGRP3, a protein that is overexpressed in uveal melanoma, and its connection to cancer signaling pathways. By understanding how RasGRP3 and Protein Kinase D (PKD) contribute to the disease, the researchers aim to identify new treatment options that could be more effective than current therapies. Patients with uveal melanoma may benefit from this research as it seeks to develop targeted therapies that address the unique genetic characteristics of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uveal melanoma, particularly those with metastatic disease.
Not a fit: Patients with other types of melanoma or those whose uveal melanoma is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients with uveal melanoma, potentially improving survival rates.
How similar studies have performed: While there has been significant progress in treating other melanoma subtypes, this approach targeting RasGRP3 and PKD in uveal melanoma is novel and has not been extensively tested.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chen, Xu — University of California, San Francisco
- Study coordinator: Chen, Xu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.